Professional Documents
Culture Documents
uiopasdfghjklzxcvbnmqwertyuiopasd
fghjklzxcvbnmqwertyuiopasdfghjklzx
cvbnmqwertyuiopasdfghjklzxcvbnmq
wertyuiopasdfghjklzxcvbnmqwertyui
opasdfghjklzxcvbnmqwertyuiopasdfg
hjklzxcvbnmqwertyuiopasdfghjklzxc
vbnmqwertyuiopasdfghjklzxcvbnmq
wertyuiopasdfghjklzxcvbnmqwertyui
opasdfghjklzxcvbnmqwertyuiopasdfg
NIFTY OUTLOOK
hjklzxcvbnmqwertyuiopasdfghjklzxc
REPORT
vbnmqwertyuiopasdfghjklzxcvbnmq
27 December 2016
wertyuiopasdfghjklzxcvbnmqwertyui
Prepared by: Meenakshi Pal
opasdfghjklzxcvbnmqwertyuiopasdfg
hjklzxcvbnmrtyuiopasdfghjklzxcvbn
mqwertyuiopasdfghjklzxcvbnmqwert
yuiopasdfghjklzxcvbnmqwertyuiopas
th
NIFTY FUTURE
NIFTY FUTURE :
PIVOT :7925
R1:7955
S1:7881
R2:7999
S2:7852
R3:8029
S3:7808
INDEX OUTLOOK
NIFTY FUTURE: The Indian Market expected to remain volatile ahead of the expiry of December series
F&O contracts, as investors roll over their positions to the January series. The near month contracts
will expire on the coming December 29. Sensex ended with a loss of 234 points at 25,807, While
Nifty closed with a loss of 77.50 points at 7,908. Nifty fell about 1% on Monday to a seven-month low
weighed by metal, realty, pharma, banking and auto stocks. The BSE Midcap and Smallcap closed
down by 2% each. The India VIX, jumped 12% to 16.9050 points after Narendra Modi's comments on
stock market's contribution to the government on Friday spooked traders. Finally it settled at 14.2350
up by 9.75%. The Rupee was trading up four paise at 67.78 per US dollar. On the global front, Asian
markets were trading mixed. Chinas Shanghai Composite index fell 0.84% to 3,279 on Monday
morning, while Japans Nikkei fell 0.09% to 19,412. Major global markets remained shut on account
of Christmas and Boxing Day holidays. In Europe, the FTSE 100 and CAC 40 were trading
marginally higher, while DAX is trading in red.
WWW.EQUITYRESEARCHLAB.COM
STRATEGY: Buy Nifty Future
above 7920 for the target of 7970 -8020 with the stop loss of 7850.
SECTORAL INDICES
INDEX (Spot)
SENSEX
NIFTY
NIFTYBANK
NIFTYIT
SUPPORT 2
25500
7800
17350
9900
CORPORATE NEWS
Lupin received tentative approval for its anti-hypersensitive drug Olmesartan Medoximil (5 mg, 20 mg and 40
mg) from the United States Food and Drug Administration (FDA) to market in the US.
ONGC announced that it will buy debt-ridden Gujarat State Petroleum Corporation's entire 80% stake in KGbasin natural gas block for an amount of $1.2 billion. Shares closed down 2.1%.
Larsen & Toubros construction arm secured projects worth a total of Rs. 3,039 Cr. The water & effluent
treatment business segment won orders worth Rs. 1,422 Cr. The power transmission & distribution business
segment secured major orders worth Rs. 1,036 Cr. The heavy civil infrastructure and metallurgical material
handling segments secured orders worth Rs. 359 Cr and Rs. 222 Cr respectively.
WWW.EQUITYRESEARCHLAB.COM
Designation
E-mail ID
Research Head
Sr. Research Analyst
Sr. Research Analyst
Tuhinanshu.jain@equityresearchlab.co.in
Yogesh.subnani@equityresearchlab.co.in
Meenakshi.pal@equityresearchlab.co.in
DISCLAIMER
The information and views in this report, our website & all the service we provide are believed to be
reliable, but we do not accept any responsibility (or liability) for errors of fact or opinion. Users have
the right to choose the product/s that suits them the most. Investment in Stocks has its own risks.
Sincere efforts have been made to present the right investment perspective. The information contained
herein is based on analysis and up on sources that we consider reliable. We, however, do not vouch
for the accuracy or the completeness thereof. This material is for personal information and we are not
responsible for any loss incurred based upon it & takes no responsibility whatsoever for any financial
profit s or loss which may arise from the recommendations above. The stock price projections shown
are not necessarily indicative of future price performance. The information herein, together with all
estimates and forecasts, can change without notice.
Equity Research Lab does not purport to be an invitation or an offer to buy or sell any financial
instrument. Analyst or any person related to Equity Research Lab might be holding positions in the
stocks recommended. It is understood that anyone who is browsing through the site has done so at his
free will and does not read any views expressed as a recommendation for which either the site or its
owners or anyone can be held responsible for. Any surfing and reading of the information is the
acceptance of this disclaimer.
Our Clients (Paid or Unpaid), any third party or anyone else have no rights to forward or share our
calls or SMS or Report or Any Information Provided by us to/with anyone which is received directly
or indirectly by them. If found so then Serious Legal Actions can be taken. Any surfing and reading of
the information is the acceptance of this disclaimer.
ALL RIGHTS RESERVED.
WWW.EQUITYRESEARCHLAB.COM